TransCode Therapeutics, Inc. (RNAZ )

Currency in USD Disclaimer
$5.09 -$0.51 (-9.11%)
Closed 06/08/2026
$4.59
$5.68
$3.85
$20.99

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol RNAZ
  • Company TransCode Therapeutics, Inc.
  • Price $5.09
  • Changes Percentage -9.11
  • Change -0.51
  • Day Low $4.59
  • Day High $5.68
  • Year High $20.99
  • Year Low $3.85
  • Market Cap $4,789,517
  • Price Avg 50 EMA (D) $7.68
  • Price Avg 200 EMA (D) $9.43
  • Exchange NASDAQ
  • Volume 2,322,513
  • Average Volume 8,891
  • Open $5.54
  • Previous Close $5.6
  • EPS -3.71
  • PE -1.36
  • Earnings Announcement 2026-08-18 12:00:00
  • Shares Outstanding $950,301

Company brief: TRANSCODE THERAPEUTICS, INC. (RNAZ )

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

RNAZ Corporation News

Income Statement